Continuous positive airway pressure (CPAP) remains the recommended first-line therapy for neonatal respiratory distress syndrome (RDS). The authors reported, however, that CPAP can fail in a substantial subset of extremely preterm infants — failure rates approach 50% as cited in the abstract. That high failure risk motivates use of second-line non-invasive options intended to reduce the need for intubation and mechanical ventilation. Clinical teams face a trade-off: escalate to invasive care with attendant risks, or apply advanced non-invasive modalities hoping to avert intubation while maintaining effective gas exchange and lung protection.
The review team summarized randomized and comparative literature showing that nasal intermittent positive pressure ventilation (NIPPV) consistently lowered rates of treatment failure and need for intubation when compared with CPAP. The authors noted the consistency of benefit across studies examining NIPPV, although the abstract did not list individual trial sizes, ventilator parameters, or pooled effect estimates. Investigators therefore described NIPPV as an established advanced non-invasive option beyond CPAP, with the reported evidence supporting its use to reduce early respiratory failure in preterm cohorts.
Nasal high-frequency oscillatory ventilation (nHFOV) also demonstrated reduced treatment failure compared with CPAP, according to the review. The abstract emphasized that reductions with nHFOV were particularly observed in extremely preterm infants. The study team did not provide detailed methodological parameters for the nHFOV trials in the abstract; specific oscillatory settings, duration of support, or objective effect sizes were not reported in the summary. Nevertheless, the authors characterized nHFOV as a viable non-invasive alternative to CPAP with physiologic differences from NIPPV and a growing evidence base.
Direct randomized head-to-head trials comparing nHFOV with NIPPV as primary respiratory support were described as lacking. Where indirect comparisons exist, the authors judged the certainty of evidence to be low. Consequently, the review team concluded that neither modality has demonstrated clear superiority over the other based on current data. Investigators therefore flagged a critical evidence gap: adequately powered, rigorously conducted head-to-head randomized controlled trials comparing nHFOV and NIPPV in extremely preterm infants are urgently needed to guide definitive clinical recommendations.
Given the absence of clear superiority, the review recommended that clinicians individualize modality choice. The authors advised that decisions should incorporate local expertise, availability of appropriate equipment, and gestational age. They further implied that unit-level experience with interface selection and ventilator platforms may influence success rates. The abstract did not specify procedural protocols, specific device brands, or interface options; such operational details were not reported in the summary and therefore cannot be inferred.
The review team explicitly identified limitations: scarce direct head-to-head randomized data and low-certainty indirect comparisons. The abstract did not provide granular trial-level data, pooled estimates, or subgroup analyses, and it did not report ventilator settings or sample sizes. Authors declared no competing interests. The primary unanswered clinical questions are concrete: which modality—NIPPV or nHFOV—yields lower treatment failure and less intubation when used as primary support in extremely preterm infants, and how do outcomes vary by gestational age and unit practice? The report closed by calling for robust head-to-head RCTs designed to answer these questions and to inform optimal primary respiratory support strategies for preterm infants with RDS.
Limitations and next steps are practical and specific. The authors asked for randomized trials with direct comparisons, and for reporting that includes ventilator settings, trial size, and clinically relevant endpoints. These are the milestones the neonatal community needs to resolve the current low certainty and to translate comparative efficacy into routine practice.